Your Cholesterol Can Look ‘Fine’—And You Can Still Be High Risk скачать в хорошем качестве

Your Cholesterol Can Look ‘Fine’—And You Can Still Be High Risk

Can LDL cholesterol look normal while your risk is still higher than expected—especially after 40? In this video, we explain ApoB vs LDL-C (cholesterol amount vs particle count) and Lp(a), the largely genetic “wildcard” that can raise cardiovascular risk even when a standard cholesterol panel looks reassuring. You’ll learn what ApoB/LDL discordance (also called particle discordance) means—when LDL-C looks okay but ApoB is higher than expected—why this can happen more often with patterns like higher triglycerides and insulin resistance, and when it may be reasonable to discuss ApoB testing (ApoB test) and/or Lp(a) testing (Lp(a) test) with your clinician calmly, without panic or internet drama. ✅ Includes a copy-paste clinician conversation script + a **hidden risk checklist to help you ask better questions and get a clearer picture of your risk profile. If you want more evidence-based, non-alarmist breakdowns like this, subscribe and watch the next video on what to do if ApoB is high or what Lp(a) actually changes—and what it doesn’t. This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Lab interpretation and decisions about testing or medication should be made with a licensed healthcare professional who knows your personal history and risk factors. Sources (official/primary links): *ESC/EAS Guidelines (2019) — Dyslipidaemias (lipid risk management framework; Lp(a) context) [ESC official guideline page](https://www.escardio.org/guidelines/c...) | [PubMed record](https://pubmed.ncbi.nlmnih.gov/31504418/) ([Sociedade Europeia de Cardiologia]) ESC/EAS Focused Update (2025) — Dyslipidaemias (updated recommendations; includes discussion of Lp(a) as a risk modifier) [ESC official focused update page](https://www.escardio.org/guidelines/c...) | [PubMed record](https://pubmed.ncbi.nlm.nih.gov/40878...) ([Sociedade Europeia de Cardiologia]) European Atherosclerosis Society (EAS) Consensus Statement (2022) — Lp(a) (evidence + practical testing guidance) [EAS consensus page](https://eas-society.org/page/lipoprot...) | [European Heart Journal article / PubMed-linked record available](https://academic.oup.com/eurheartj/ar...) ([EAS]) National Lipid Association (NLA) Expert Clinical Consensus (2024) — ApoB (apoB in ASCVD risk assessment and management decisions) [NLA official page](https://www.lipid.org/nla/role-apolip...) | [PubMed record](https://pubmed.ncbi.nlm.nih.gov/39256...) ([Associação Nacional de Lipídios]) AHA / Circulation (2024) — ApoB review (“Bridging the Gap…”) (apoB and clinical risk prediction/practice) [AHA Circulation article](https://www.ahajournals.org/doi/10.11...) | [PubMed record](https://pubmed.ncbi.nlm.nih.gov/38950...) ([Ahá Journals]) ACC Expert Consensus Decision Pathway (2022) (U.S. lipid management context; nonstatin LDL-C lowering framework) [JACC article](https://www.jacc.org/doi/10.1016/j.ja...) | [PubMed record](https://pubmed.ncbi.nlm.nih.gov/36031...) ([Jornal do Colégio Americano de Cardiologia]) Canadian Cardiovascular Society Guideline (2021) — Dyslipidemia (ApoB/non-HDL-C in elevated triglycerides; Lp(a) once-in-lifetime screening context) [CJC full text](https://onlinecjc.ca/article/S0828-28...) | [CCS guideline hub](https://ccs.ca/guideline/2021-lipids/) ([onlinecjc.ca]) HASHTAGS #cholesterol #ApoB #LipoproteinA #HeartHealth #Over40Health #LDL #CardiovascularHealth #Prevention #MetabolicHealth #Triglycerides #Prediabetes #FamilyHistory #Atherosclerosis #HealthEducation #AskYourDoctor